Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients
Anguera, Georgia (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Mulet Gual, Maria (Institut de Recerca Sant Pau)
Zamora, Carlos (Institut de Recerca Sant Pau)
Osuna Gómez, Rubén (Institut de Recerca Sant Pau)
Barba Joaquin, Andrés (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Sullivan, Ivana (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Serra, Jorgina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Cantó, Elisabet (Institut de Recerca Sant Pau)
Vidal, Silvia (Institut de Recerca Sant Pau)
Majem, Margarita (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Universitat Autònoma de Barcelona

Data:	2024
Resum:	PD-(L)1 inhibitors are part of the treatment strategy for non-small cell lung cancer (NSCLC) although its efficacy is limited to certain patients. Our study aimed to identify patients who might benefit from anti-PD-(L)1 inhibitors by analyzing the PD-L1 expression on circulating leukocytes and its evolution during treatment. One hundred thirteen NSCLC patients, according to their radiological response after 10-12 weeks of treatment, were classified into responders, stable, and progressive disease. Percentages of circulating PD-L1 leukocytes, PD-L1 platelets (PLTs), and leukocyte-PLT complexes were assessed using flow cytometry, and plasma concentrations of soluble immunomodulatory factors were quantified by ELISA. Responders exhibited significantly higher pre-treatment percentages of PD-L1 neutrophils, PD-L1 CD14 cells, and PD-L1 PLTs than progressors. The percentages of these populations decreased in responders post-treatment, contrasting with stables and progressors. PLTs notably contributed to PD-L1 expression in CD14 cells and neutrophils. Plasma cytokine analysis revealed baseline differences only in IL-17 concentration among groups, whereas network analyses highlighted distinct association patterns between plasma molecules and PD-L1 leukocytes after 10-12 weeks of treatment. Our findings suggest that pre-treatment assessment of circulating PD-L1 neutrophils, PD-L1 CD14 cells, and PD-L1 PLTs may be helpful in identifying NSCLC patients who are potential candidates for anti-PD-(L)1 therapy.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	NSCLC ; PD-L1+ CD14+ cells ; PD-L1+ neutrophils ; PDL-1+ platelets ; Immunotherapy
Publicat a:	Biomedicines, Vol. 12 Núm. 5 (may 2024) , p. 958, ISSN 2227-9059

DOI: 10.3390/biomedicines12050958
PMID: 38790920

17 p, 2.7 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats